Gilead Sciences (GILD) News Today $111.73 -1.27 (-1.13%) As of 01:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GILD Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period US FDA places clinical hold on 2 Gilead trials of weekly HIV pill combinationJune 10 at 12:45 PM | reuters.comGilead Sciences shares hit after HIV studies placed on hold by FDAJune 10 at 12:45 PM | finance.yahoo.comGilead Sciences (NASDAQ:GILD) Shares Gap Down - Time to Sell?Gilead Sciences (NASDAQ:GILD) Shares Gap Down - Should You Sell?June 10 at 11:57 AM | marketbeat.comGilead shares fall after FDA places clinical hold on HIV treatment trialsJune 10 at 10:29 AM | proactiveinvestors.comCantor Fitzgerald Predicts Gilead Sciences FY2026 EarningsGilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Gilead Sciences in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst C. Gould expects that the biopharmaceutical company will post eaJune 10 at 8:57 AM | marketbeat.comAtwood & Palmer Inc. Has $38.67 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Atwood & Palmer Inc. trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 345,067 shares of the biopharmaceutical company's sJune 10 at 8:36 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Handelsbanken Fonder ABHandelsbanken Fonder AB grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 85.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,094,880 shares of the biopharmaceutical companJune 10 at 8:28 AM | marketbeat.comAvanza Fonder AB Sells 7,454 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Avanza Fonder AB lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 119,661 shares of theJune 10 at 7:38 AM | marketbeat.comAbacus FCF Advisors LLC Purchases 36,309 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Abacus FCF Advisors LLC lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 28.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 162,186 shares of the biopharmaceutical company's stock after acquiring an additional 36,309June 10 at 7:37 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by MADDEN SECURITIES CorpMADDEN SECURITIES Corp lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 32.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,155 shares of the biopharmaceutical company'sJune 10 at 6:58 AM | marketbeat.comFourpath Capital Management LLC Has $1.17 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)Fourpath Capital Management LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 21.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,423 shares of the biopharmaceutical company's stock after selling 2,847 shares duJune 10 at 6:24 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Cardinal Capital Management Inc.Cardinal Capital Management Inc. lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 82.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,250 shares of the biopharmaceutical company's stockJune 10 at 6:24 AM | marketbeat.comYousif Capital Management LLC Sells 3,236 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Yousif Capital Management LLC trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 147,738 shares of the biopharmaceutical companyJune 10 at 6:11 AM | marketbeat.comTounjian Advisory Partners LLC Invests $424,000 in Gilead Sciences, Inc. (NASDAQ:GILD)Tounjian Advisory Partners LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 3,782 shares of the biopharmaceutical company's stock, valued at approJune 10 at 5:59 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Stock Position Lifted by Farther Finance Advisors LLCFarther Finance Advisors LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 94.3% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 37,487 shares of the biopharmaceutical company's stock after purcJune 10 at 5:51 AM | marketbeat.comCHICAGO TRUST Co NA Invests $258,000 in Gilead Sciences, Inc. (NASDAQ:GILD)CHICAGO TRUST Co NA purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The firm purchased 2,303 shares of the biopharmaceutical company's stock, valued at approximately $258,000. A number of otheJune 10 at 5:40 AM | marketbeat.comOLD National Bancorp IN Sells 5,365 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)OLD National Bancorp IN decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 30.8% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,030 shares of the biopharmaceuticalJune 10 at 4:37 AM | marketbeat.comRange Financial Group LLC Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)Range Financial Group LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 50.1% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 15,951 shares of the biopharmaceutical company's stock after buyingJune 9 at 7:43 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Foundation Resource Management Inc.Foundation Resource Management Inc. cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 47.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 109,916 sharesJune 9 at 7:03 AM | marketbeat.comPark Avenue Securities LLC Raises Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Park Avenue Securities LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 41.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 40,533 shares of the biopharmaceutical company'sJune 9 at 5:51 AM | marketbeat.comWedmont Private Capital Grows Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Wedmont Private Capital grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 20.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,259 shares of the biopharmaceutical company's stJune 9 at 5:15 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Capital Investment Advisors LLCCapital Investment Advisors LLC cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 353,006 shares of the biopharmaceutical company's stoJune 8 at 9:01 AM | marketbeat.comCentral Bank & Trust Co. Reduces Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Central Bank & Trust Co. cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 30.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,977 shares of the biopharmaceutical cJune 8 at 8:52 AM | marketbeat.comWedge Capital Management L L P NC Reduces Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Wedge Capital Management L L P NC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 300,716 shares of the biopharmaceutical company's stockJune 8 at 8:25 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Vest Financial LLCVest Financial LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 73.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,392 shares of the biopharmaceutical companJune 8 at 4:41 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the twenty-seven analysts that are currently covering the company, MarketBeat.com reports. Nine investment analysts have rated the stock with a hold recommendation, fifteenJune 8 at 3:27 AM | marketbeat.comProcyon Advisors LLC Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Procyon Advisors LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.1% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 22,947 shares of the biopharmaceutical company's stock after selling 11,36June 7 at 5:37 AM | marketbeat.com2,300 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Chesley Taft & Associates LLCChesley Taft & Associates LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 2,300 shares of the biopharmaceutical company's stock, valued at approximately $258,000. SJune 7 at 4:51 AM | marketbeat.com2 Reasons to Like GILD (and 1 Not So Much)June 6, 2025 | uk.finance.yahoo.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Intellectus Partners LLCIntellectus Partners LLC lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 27.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,204 shares of the biopharmaceuticalJune 6, 2025 | marketbeat.comA New Shot Prevents HIV—and Breathes New Life Into a Stagnant BiotechJune 6, 2025 | msn.comHudson Capital Management LLC Has $6.03 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)Hudson Capital Management LLC cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,792 shares of the biopharmaceutical company'sJune 6, 2025 | marketbeat.com5,080 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Curat Global LLCCurat Global LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 5,080 shares of the biopharmaceutical company's stock, valuedJune 6, 2025 | marketbeat.comE. Ohman J or Asset Management AB Sells 3,700 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)E. Ohman J or Asset Management AB lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 53,890 shares of the biopharmaceJune 6, 2025 | marketbeat.comLmcg Investments LLC Decreases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)Lmcg Investments LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 69.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,113 shares of the biopharmaceutical company's stockJune 6, 2025 | marketbeat.comPositive Outlook Boosted Gilead Sciences (GILD) in Q1June 5, 2025 | insidermonkey.comFluent Financial LLC Sells 3,334 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Fluent Financial LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.4% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 25,822 shares of the biopharmaceutical company's stock after selJune 5, 2025 | marketbeat.comMerit Financial Group LLC Buys 9,522 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Merit Financial Group LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 48.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,229 shares of the biopharmaceutical company's stock afterJune 5, 2025 | marketbeat.comGilead Sciences’ Oncology Advancements: Trodelvy’s Potential to Boost Stock ValueJune 5, 2025 | tipranks.comGilead Sciences, Inc. (GILD) Jefferies Global Healthcare Conference (Transcript)June 4, 2025 | seekingalpha.comIs Gilead Sciences Stock Outperforming the S&P 500?June 4, 2025 | msn.comGilead Short Strangle Could Net $395 In Short OrderJune 4, 2025 | msn.comIams Wealth Management LLC Decreases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Iams Wealth Management LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,180 shares of the biopharmaceuticalJune 4, 2025 | marketbeat.comContravisory Investment Management Inc. Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)Contravisory Investment Management Inc. acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 5,261 shares of the biopharmaceutical coJune 4, 2025 | marketbeat.comNBC Securities Inc. Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD)NBC Securities Inc. raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 60,592.9% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,497 shares of the biopharmaceuticalJune 4, 2025 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O'day Sells 10,000 SharesGilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the transaction, the chief executive officer now owns 620,268 shares of the company's stock, valued at $68,489,992.56. This represents a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.June 3, 2025 | marketbeat.comHealthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCOJune 3, 2025 | cnbc.comAEGON ASSET MANAGEMENT UK Plc Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)AEGON ASSET MANAGEMENT UK Plc raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 285,817 shares of the biopharmaceutical comJune 3, 2025 | marketbeat.comCGN Advisors LLC Decreases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)CGN Advisors LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 15.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,171 shares of the biopharmaceutical company's stock afterJune 3, 2025 | marketbeat.comUnigestion Holding SA Buys New Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Unigestion Holding SA bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 38,596 shares of the biopharmaceutical company's stock, valued at approxJune 3, 2025 | marketbeat.com Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address GILD Media Mentions By Week GILD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GILD News Sentiment▼1.330.68▲Average Medical News Sentiment GILD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GILD Articles This Week▼4031▲GILD Articles Average Week Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AMGN News Today VRTX News Today REGN News Today ALNY News Today BIIB News Today UTHR News Today INCY News Today NBIX News Today EXEL News Today BMRN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GILD) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the sa...Crypto 101 Media | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Secret WeaponThe Trump-Elon War Could Trigger an Economic Collapse - Here's Your Only Safe Exit This isn't just a war of...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy 2026 will be a disaster for many Americans2025 Market Crash The first-quarter stock crash left investors wondering what lies ahead. Today 50-year Wal...Chaikin Analytics | SponsoredElon’s “Secret Mission”Tesla, SpaceX and Starlink made billions for investors... But a meeting Elon had on March 21st, 2025, could...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gilead Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
